Auranofin and Sirolimus in Treating Patients With Advanced Solid Tumors or Recurrent Non-Small Cell Lung Cancer
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase I clinical trial studies the side effects and best dose of auranofin and sirolimus
when given together in treating patients with non-small cell lung cancer. Immunosuppressive
therapy, such as auranofin and sirolimus, may be an effective treatment for non-small cell
lung cancer. Sirolimus may also stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth. Giving auranofin and sirolimus may be an effective treatment
for non-small cell lung cancer.